NSD3 and lung carcinoma: Both PROTAC were synthesized incorporating an NSD3-PWWP antagonist link to an E3 ligase, showing the degradation of both NSD3 isoforms in cell lines of AML, multiple myeloma, and lung cancer [85,86].